LSE:GSKPharmaceuticals
GSK Respiratory Expansion Tests Valuation As Arexvy Access And Exdensur Grow
GSK received European Commission approval to extend its RSV vaccine Arexvy to adults aged 18 and over across Europe.
The company launched Exdensur, a twice-yearly biologic for severe asthma, supported by new pharmacy partnerships.
These moves expand GSK's respiratory portfolio and open new commercial channels in key European markets.
LSE:GSK is trading at £19.455, with the share price up 4.5% over the past week and 6.2% over the past month. Over longer periods, the stock has returned 47.2%...